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Abstract
Inflammatory choroidal neovascular membranes are challenging to diagnose and manage. A number of uveitic entities
may be complicated by the development of choroidal neovascularization leading to a decrease in central visual acuity.
In conditions such as punctate inner choroidopathy, development of choroidal neovascularization is extremely common
and must be suspected in all cases. On the other hand, in patients with conditions such as serpiginous choroiditis, and
multifocal choroiditis, it may be difficult to differentiate between inflammatory choroiditis lesions and choroidal
neovascularization. Multimodal imaging analysis, including the recently introduced technology of optical coherence
tomography angiography, greatly aid in the diagnosis and management of inflammatory choroidal neovascularization.
Management of these neovascular membranes consists of anti-vascular growth factor agents, with or without
concomitant anti-inflammatory and/or corticosteroid therapy.
Keywords: Inflammatory choroidal neovascularization, Uveitis, Posterior uveitis, Choroiditis, Indocyanine green
angiography, Fluorescein angiography, Optical coherence tomography angiography, EDI-OCT
Review
Introduction
Choroidal neovascular membranes (CNV) represent the
pathological growth of blood vessels and can result in
loss of visual function. A diverse array of pathological
processes involving the retinal pigment epithelium (RPE)
and Bruch’s membrane may lead to the formation of
CNV. Age-related macular degeneration (AMD) and
myopia are the conditions that most commonly lead to
the development of CNV, with ocular inflammation
being the next most frequently implicated [1–3]. CNV
may occur in a wide range of uveitides including both
infectious and non-infectious etiologies. Notably, the in-
cidence of CNV in posterior uveitis varies considerably
depending upon the underlying pathological mechanism.
For instance, the development of CNV is intricately
connected to the morbidity associated with punctate inner
choroidopathy (PIC) [4]. Other conditions that can be
complicated by the development of CNV include multi-
focal choroiditis, serpiginous choroiditis, presumed ocular
histoplasmosis syndrome (POHS), toxoplasma retinochor-
oiditis, and Vogt-Koyanagi-Harada (VKH) disease [5].
Inflammatory CNV (i-CNV) can occur either directly
from an angiogenic stimulus mediated by local inflam-
mation, result from a degenerative disruption in the
Bruch’s membrane–RPE complex, or both [2, 6]. Neo-
vascular buds grow through the damaged RPE–Bruch’s
complex and proliferate to develop large branching
vascular networks. These vessels progressively grow and
leak, leading to the accumulation of fluid in the subret-
inal space.
The diagnosis of CNV in inflammatory eye conditions
was historically challenging. Recently, the ocular imaging
tools by which clinicians diagnose and manage CNV
have undergone significant advances. For example, the
development of optical coherence tomography angiog-
raphy (OCTA) provides a highly valuable instrument to
monitor the progression of CNV. Furthermore, there
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has been a rapid expansion in the available treatment
modalities for i-CNV. In the past, laser photocoagulation
and surgical excision were the only techniques employed
in the management of i-CNVs. Treatment with intravit-
real anti-vascular endothelial growth factor (VEGF)
injections are now the mainstream in the management
of i-CNVs. Other therapeutic strategies include photo-
dynamic therapy (PDT) and corticosteroids/immunosup-
pressive agents (local and/or systemic) [1].
In this index review, a comprehensive overview of the
epidemiology, clinical features, imaging characteristics,
and management options of inflammatory choroidal
neovascular membranes has been performed.
Epidemiology of inflammatory CNV
CNV is an important sequela of a wide range of oph-
thalmic pathologies. The most common cause of CNV
in the elderly is age-related macular degeneration, while
in the young, CNV is frequently identified as secondary
to high myopia, hereditary disorders, angioid streaks,
and inflammation [7, 8]. Given the propensity of un-
treated CNV to result in rapid irreversible central vi-
sion loss, the importance of characterizing risk factors
for CNV and prompt diagnosis is well-recognized [5].
Indeed, central vision loss due to CNV compromises
patients’ ability to participate in certain types of work,
as well as other daily activities such as reading and
driving [9]. Uveitis tends to affect a working age popu-
lation, and thus i-CNV frequently afflicts patients dur-
ing their most productive and active years [5].
Various causes of infectious and non-infectious
i-CNVs have been listed in Table 1 [10].
Infectious uveitis
I-CNV can be secondary to either infectious or non-
infectious uveitis. Causes of infectious uveitis that re-
sult in CNV include histoplasmosis, toxoplasmosis,
toxocariasis, tuberculosis, congenital rubella, and
West Nile virus [11–16]. Published data on the preva-
lence of i-CNV secondary to infectious uveitis are
scarce, with case series and case reports dominating
the literature. Furthermore, prevalence is likely to be
geographically specific, with higher rates of presumed
ocular histoplasmosis syndrome (POHS) reported in
American and European populations and higher rates
of toxoplasmosis reported in South Asia [7, 17, 18].
Table 2 summarizes the common clinical features,
features of i-CNVs, and associated manifestations as
reported in the literature.
Non-infectious uveitis
The prevalence of CNV secondary to non-infectious
uveitis is better defined. In a retrospective multicenter
cohort study of 15,137 non-infectious uveitic eyes,
Baxter and colleagues report that 2% of patients present-
ing with posterior or panuveitis had either active CNV
or sequelae of past CNV [5]. In contrast, CNV was iden-
tified very rarely at the presentation in cases of anterior
or intermediate uveitis [5]. Causes of non-infectious uve-
itis that result in CNV include Vogt-Koyanagi-Harada’s
disease, punctate inner choroidopathy, multifocal chor-
oiditis, geographic helicoid peripapillary choroidopathy,
and acute posterior multifocal placoid pigment epithe-
liopathy [1, 18]. Vogt-Koyanagi-Harada disease and
punctate inner choroidopathy have been associated
with the highest incidence of CNV among these non-
infectious uveitides, with adjusted hazard ratios of 3.37
and 8.67 respectively [5]. Various common causes of non-
infectious uveitides associated with i-CNV are listed in
Table 3 along with their prominent characteristic
features.
Table 1 Various uveitic entities associated with inflammatory
choroidal neovascular membranes
Non-infectious Choroiditis Multifocal choroiditis
Punctate inner choroidopathy
Acute multifocal placoid
pigment epitheliopathy
Birdshot chorioretinitis
Multiple evanescent white
dot syndrome
Stromal choroiditis Vogt-Koyanagi-Harada
syndrome
Sympathetic ophthalmia
Panuveitis Behcet’s disease
Sarcoidosis
Multifocal choroiditis
with panuveitis
Miscellaneous Idiopathic panuveitis
Tubulointerstitial nephritis
and uveitis
Infectious Bacterial Mycobacterium tuberculosis
(serpiginous choroiditis)
Protozoal Toxoplasmosis
Viruses West Nile virus
Rubella retinopathy
Fungi Candida albicans
Histoplasma capsulatum
(presumed ocular
histoplasma syndrome)
Cryptococcus neoformans
Aspergillus fumigatus
Helminth Toxocara
Others Endophthalmitis
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Clinical features of inflammatory choroidal neovascularization
Signs and symptoms
Classically, i-CNV lesions present when the patient com-
plains of new-onset distortion or metamorphopsia.
Sometimes, it may lead to the diminution of vision or a
scotoma which is unexplained by the uveitis lesion.
Many lesions, especially extrafoveal i-CNVs may be
asymptomatic and may be detected only by clinical
examination or imaging alone. i-CNVs are usually
reported with posterior or panuveitis, as well as in cer-
tain cases of intermediate uveitis. Commonly, i-CNVs
are diagnosed in a patient on follow-up for uveitis, in
which case the CNV lesion may be missed initially due
to the presence of associated features such as inflamma-
tory lesions, scars, and pigmentation, as well as intra- or
subretinal fluid accumulation [19]. On the contrary,
Invernizzi et al. [20] recently demonstrated in three
cases that the detection of CNV without associated
AMD features (such as drusen) led the authors to per-
form additional imaging, such as ICGA, which showed
the presence of choroidal stromal inflammation leading
to the diagnosis of presumed tubercular choroiditis.
i-CNV lesions are usually closely associated with chor-
ioretinal lesions such as scars, lesions, or choroidal
Table 2 Features of inflammatory choroidal neovascularization (CNV) commonly associated with infectious uveitis
Presumed Ocular
Histoplasmosis Syndrome
(POHS) [135–138]
Toxoplasmosis
[88, 124, 139, 140]
Intraocular tuberculosis
[20, 93, 141, 142]
West Nile virus
chorioretinitis [143–145]
Prevalence Frequent; present in majority
cases
Estimated between 0.3–19% Uncommon; prevalence
not known
Only few cases (< 5) reported
Location
of CNV
CNV is seen at the edge of
a pre-existing scar in the
macular or peripapillary region
CNV typically grows close
to the edge of an atrophic
chorioretinal scar
CNV is typically adjacent
to the healed choroidal
granuloma or to a healed
choroiditis scar
CNV is adjacent to chorioretinal
scars
Morphology
of CNV
Active lesions have a disciform
appearance at the macula, with
a green-gray subretinal lacy
discoloration and surrounding
pigment. Inactive CNV appears
as a white disciform scar with
fibrovascular tissue
Active CNV appears as an
outer retinal lesion close to
the scar with associated
hemorrhages and intra- or
subretinal fluid.
CNV may present as a
subretinal lesion with
hemorrhages and intra-
or subretinal fluid. Rarely,
type 1 CNV may be
detected only using
imaging
CNV presents as a chorioretinal
lesion with subretinal fluid and
area of retinal hemorrhage
Associated
inflammatory lesions
The triad of POHS includes the
presence of peripapillary
atrophy or pigmentation, histo
spots (focal round-shaped
chorioretinal lesions), and
absence of overlying vitritis
Recurrent disease appears as
an oval or circular whitish
focal area of retinochoroiditis
in the periphery of old atrophic
lesions; dense overlying vitritis
(headlight-in-fog); perivasculitis
with diffuse venous sheathing;
segmental arteriolar plaques
Choroiditis may have
amoeboid lesions with
central healing and active
margins (serpiginous
choroiditis) or it may
present with choroidal
granulomas
There is multifocal chorioretinitis
with vitritis; multiple active
chorioretinal lesions have the
appearance of deep, creamy
lesions and are 200–1000 μm in
size. Inactive lesions are partly
atrophic and partly pigmented
with a “target-like appearance.”
Table 3 Features of inflammatory choroidal neovascularization (CNV) commonly associated with non-infectious uveitis
Multifocal choroiditis
[74, 146, 147]
Punctate inner choroidopathy
(PIC) [74, 146]
Serpiginous choroiditis
[148–150]
Vogt-Koyanagi-Harada disease
(VKH) [151–153]
Prevalence 33–50% cases 76–100% cases 10–25% cases 9–15%
Location of
CNV
Associated with inflammatory
lesions in the subfoveal or
extrafoveal region
Highly focal; associated
with inflammatory lesions
in the macula
CNV is located near
chorioretinal lesions in
peripapillary, subfoveal,
or extrafoveal areas
Usually extrafoveal; can
be subfoveal and associated
with chorioretinal scar
Morphology
of CNV
CNV appear as subretinal elevations
and subretinal fluid with or without
associated hemorrhage, closely
resembling inflammatory lesions
CNV appear as subretinal
elevations and subretinal
fluid with or without
hemorrhage, closely
resembling inflammatory
lesions
CNV lesions are deep
with associated
chorioretinal atrophy,
subretinal fibrosis, and
pigment clumping
CNV lesions are deep, associated
with subretinal or intraretinal
fluid, with hemorrhage and
exudation.
Associated
inflammatory
lesions
Multifocal choroiditis present with
minimal vitreous inflammation with
multiple punched-out, white-yellow
lesions (50–200 μm) in the
peripapillary, mid-peripheral, and
anteriorly to the equator
The lesions are characterized
by multiple, small (50–300
μm in diameter), yellow or
white, opaque, round lesions
scattered throughout the
posterior pole, rarely extending
to mid-periphery; absence
of vitritis
Active lesions appear as
gray-white lesions that
progress in a geographic
manner in the posterior
fundus
VKH presents with granulomatous
anterior uveitis, posterior synechiae,
iris nodules, and stromal atrophy;
multiple pockets of subretinal
fluid with exudative detachments;
sunset glow fundus in the
chronic disease.
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granulomas. These lesions can be subfoveal, extrafoveal,
or juxtafoveal, and are highly focal. These can be associ-
ated with intra- or subretinal hemorrhages and exudation
surrounding the lesion. Healed or inactive i-CNVs can re-
sult in subretinal yellow-white scars, which may be associ-
ated with fibrosis and pigmentation. The presence of
intra- or subretinal fluid with i-CNV, as well as serous
retinal detachment, may also represent signs of inflamma-
tion, leading to a misdiagnosis during cursory examination
[1, 10, 19].
Contrasting features of i-CNV and neovascular AMD
Patients with AMD-associated CNV have certain differ-
ences compared to i-CNVs. Usually, CNVs among
patients with AMD can be characterized as type 1 (sub-
retinal), type 2 (outer retinal), or mixed based on clinical
and examination (including imaging) findings [21]. A
majority of i-CNVs are type 2 lesions with abnormal
growth of vasculature into the outer retinal space. AMD
CNVs are usually subfoveal and are associated with the
presence of drusen and retinal pigment epithelial abnor-
malities due to the accumulation of lipofuscin material.
On the other hand, the retinal pigment epithelium is
often intact in individuals with i-CNV [19]. The pro-
posed mechanism of development of i-CNV is the focal
breach of the retinal pigment epithelium due to infec-
tion/inflammation leading to growth and entry of new
vessels into the outer retinal space [19, 22, 23]. Since
i-CNV lesions are highly focal, they may respond to
fewer therapeutic interventions such as the lesser num-
ber of injections compared to AMD patients (as shown
by experiences of various authors in Table 4).
Patients with AMD develop CNV due to various con-
tributory factors such as inflammation, complement dys-
regulation, and growth factor drives such as VEGF drive.
Therefore, patients with AMD require constant suppres-
sion of VEGF with multiple injections of anti-VEGF
agents [24, 25]. In contrast, in patients with i-CNV, with
control of inflammation, which primarily drives the
development of the CNV, it may be possible that the
neovascular drive is extinguished once the inflammation
is adequately controlled.
In the context of AMD, various multicenter clinical
trials and their extension studies have shown that
these patients often require anti-VEGF therapy for
several years [26–30]. For instance, the SEVEN-UP
study (n = 65), a multicenter, non-interventional co-
hort study, examined the long-term results of patients
7 years after entering the ANCHOR/MARINA trials
with monthly anti-VEGF therapy. In this study, 37%
eyes maintained visual acuity ≥ 20/70. Sixty-eight per-
cent of study eyes had active exudative disease [27].
In contrast, there are no such long-term reports in
patients with uveitis due to i-CNVs.
Imaging features of inflammatory choroidal neovascularization
Fluorescein angiography
Traditionally, fluorescein angiography (FA) has been
widely employed in the diagnosis of CNV secondary to
various pathologies such as AMD. In AMD, the patterns
of CNV include classic (subretinal) or occult CNV (sub-
RPE). However, on FA, it may not be possible to
characterize the membranes into one of the two categor-
ies easily, and therefore, some membranes are referred
to as predominantly classic or minimally classic and
occult with no classic types [31]. Active CNV lesions of
AMD show the leakage of the dye with early hyperfluor-
escence, which may appear to be from an undetermined
source in the occult (type 1) CNVs.
The appearance of CNV in posterior uveitis on FA has
not been as well characterized. CNV lesions on FA
present with early iso- or hyperfluorescence with late
leakage (Fig. 1) [32]. The presence of surrounding mild
hemorrhage causing masking effect on FA may also lead
to the diagnosis of CNV. However, the inflammatory
retinochoroidal lesions of posterior uveitis may present
with markedly similar findings making the differentiation
very challenging. Active uveitic chorioretinal lesions
show early isofluorescence (but mostly hypofluorescent)
with late leakage. On the other hand, inactive atrophic
lesions show early hypo-/isofluorescence with late stain-
ing (indicating RPE window defect) without any leakage
[1–3]. Thus, there are very subtle differences in the ap-
pearance of FA between CNV lesions and active/inactive
retinochoroidal inflammatory lesions. In the presence of
extensive retinal involvement resulting in scars and pig-
mentary changes, which may happen in conditions like
multifocal choroiditis, serpiginous choroiditis, and VKH
disease, the detection of hyperfluorescence due to CNV
may be very challenging.
In summary, FA in the detection of CNV in inflamma-
tory conditions may be inconclusive. Additional tests
such as OCT and OCTA may be needed to initiate ther-
apy for CNV lesions and a multimodal imaging ap-
proach is always recommended.
Indocyanine green angiography
Indocyanine green (ICG) angiography is an imaging
technique that allows a better visualization of the chor-
oid compared to fluorescein angiography [33]. The use
of ICG angiography in uveitis permits the identification
of choroidal abnormalities such as granulomas, chorio-
capillaris hypoperfusion, active choroiditis, and hyper-
permeability [34]. Neovascular networks composing CNVs
are also clearly visualized by ICG, with this technique
showing better results in detecting occult lesions com-
pared to fluorescein angiography (Fig. 2) [35].
I-CNVs are mainly represented by classic lesions and
are usually clearly visualized by fluorescein angiography
Agarwal et al. Journal of Ophthalmic Inflammation and Infection  (2018) 8:13 Page 4 of 18
[1, 32]. However, a recent study on idiopathic CNVs
which share several clinical features with i-CNVs
showed that ICG was more accurate than fluorescein
angiography in evaluating the size of the neovascular
lesions. Furthermore, a reduction of more than 33%
in the size of the CNV, measured by ICG angiography
2 months after initiating the treatment, was associated
with a favorable outcome [36]. In select cases, ICG
angiography can be used to augment the evaluation
and follow-up of i-CNVs, identifying possible occult
components and allowing these lesions to be differen-
tiated from recurrent inflammatory lesions [37].
In summary, ICG helps to identify both i-CNVs and
their associated choroidal alterations in patients with
uveitis, thereby allowing a more comprehensive evalu-
ation of the disease.
Optical coherence tomography
The introduction of optical coherence tomography
(OCT) into clinical practice has profoundly impacted
Table 4 Summary of studies showing the efficacy of anti-vascular endothelial growth factor therapy in inflammatory choroidal
neovascularization (studies with sample size ≥ 5 eyes)
Author (year);
country
Design; sample
size
Disease Mean no of injections;
agent
Mean follow-
up
Efficacy outcomes
Roy et al. (2017);
India [18]
Retrospective; 30
eyes (28 patients)
Idiopathic choroiditis, toxo
plasmosis, panuveitis, VKH,
serpiginous choroiditis
2.76; (bevacizumab,
ranibizumab)
17.93 ±
14.28 months
Improvement in visual
acuity in 53.3%; stabilization
in 26.6%
Korol et al. (2017);
Ukraine [154]
Prospective
cohort; 15 eyes
(14 patients)
Toxoplasmosis 1.7 (aflibercept) 12 months Visual acuity improved
from 0.36 to 0.64
(p = 0.0002)
Parodi et al. (2014);
Italy [76]
Prospective; 7
eyes (7 patients)
Serpiginous choroiditis 1 injection in 12 months
(bevacizumab)
12 months Visual acuity improvement
in 52% and stabilization
in 57%
Mansour et al. (2012);
Lebanon [155]
Retrospective; 8
eyes (8 patients)
VKH, PIC, toxoplasmosis 1.375 (bevacizumab) 5 years Visual acuity improved
(median gain of 3.8 lines)
Iannetti et al. (2013);
Italy [156]
Prospective
study; 8 eyes
(8 patients)
Posterior uveitis 3.75 ± 1.38 (bevacizumab) 19.25 ±
6 months
Visual acuity improved
from 0.27 to 0.5 (p < 0.05)
Julian et al. (2011);
France [157]
Retrospective; 15
eyes (15 patients)
Multifocal choroiditis with
panuveitis, ampiginous
choroiditis, and others
4.25 (in 12 eyes); 3 eyes
received only 1 injection
(bevacizumab)
17.6 months Visual acuity improved
from 0.53 to 0.29
Cornish et al. (2011);
UK [158]
Retrospective; 9
eyes (9 patients)
PIC 2.34 injections per year
(bevacizumab and
ranibizumab)
14.9 months Visual acuity gain was 0.36
LogMAR units
Kramer et al. (2010);
Israel [159]
Retrospective; 10
eyes (10 patients)
Multifocal choroiditis, PIC,
toxoplasmosis, POHS,
serpiginous choroiditis,
and panuveitis
2.7 ± 2 (bevacizumab) 13 ±
8 months
Visual acuity improved
from 0.87 ± 0.74 to 0.38 ± 0.63
(p = 0.005)
Lott et al. (2009);
USA [160]
Retrospective; 34
eyes (30 patients)
Multifocal choroiditis, PIC,
VKH, idiopathic panuveitis,
sarcoidosis, serpiginous
choroiditis, toxocariasis,
POHS, CMV retinitis, and
others
2 (bevacizumab) 7 months At 6 months, visual acuity
improved in 17% and
stabilized
in 33%
Doctor et al. (2009);
USA [161]
Retrospective; 6
eyes (5 patients)
Idiopathic panuveitis, birdshot
chorioretinopathy, sympathetic
ophthalmia, VKH, and multifocal
choroiditis and panuveitis
2.7 (bevacizumab) 15.3 months Visual acuity improved in
60% of cases
Fine et al. (2009);
USA [95]
Retrospective; 6
eyes (5 patients)
Multifocal choroiditis 2.3 (bevacizumab) 6 months 5/6 eyes improved to 20/30
acuity or better at 6 months
Schadlu et al. (2008);
USA [87]
Retrospective; 28
eyes (28 patients)
POHS 1.8 (bevacizumab) 22.43 weeks Visual acuity improved from
0.65 to 0.43 LogMAR units
Adan et al. (2007);
Spain [162]
Retrospective; 9
eyes of 9 patients
PIC, serpiginous choroiditis,
multifocal choroiditis, POHS,
and birdshot chorioretinopathy
7 eyes received 1
injection (bevacizumab)
7.1 months CNV resolved completely in
100% affected eyes
CNV choroidal neovascularization, CMV cytomegalovirus, PIC punctate inner choroidopathy, POHS presumed ocular histoplasmosis syndrome, VKH
Vogt-Koyanagi-Harada’s disease
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the management of retinal and choroidal diseases. This
technique allows clinicians to obtain quasi-histological
sections of the ocular structure in a non-invasive and
highly repeatable way [38]. For this reason, OCT per-
mits the evaluation of pathological changes of ocular
structures and provides a means of assessing responses
to treatment. A development of the OCT technique,
the “enhanced depth imaging” (EDI) modality, can be
used to evaluate choroidal thickness and structural
modifications and is particularly useful in the manage-
ment of uveitis [39].
I-CNV usually develops between the retinal pigment
epithelium (RPE) and the neurosensory retina, with im-
aging features comparable to those of classic (type 2)
CNVs [1, 18, 40]. On OCT images, these lesions appear
as hyper-reflective structures anterior to a disrupted
RPE, with solid tissue visualized in the subretinal space
(Figs. 2 and 3) [40, 41]. One distinctive OCT feature of
i-CNV that helps to distinguish these cases from other
type 2 CNVs is the “pitchfork sign.” This sign describes
finger-like hyper-reflective projections extending from
the CNV area into the outer retinal layers [42]. In a frac-
tion of those cases of CNV as a sequela of uveitis, an
occult component of the membrane can be present,
appearing as a pigmented epithelial detachment with
mixed content [18].
On OCT scans, the activity of CNV is associated
with signs of exudation such as retinal thickening,
subretinal fluid, intraretinal fluid, intraretinal flecks,
and low reflectivity or undefined boundaries of the
subretinal material (Fig. 2) [41, 43]. The presence of
these features correlate with the leakage on fluores-
cein angiography and can be used to monitor CNV
progression and response to therapy [43]. In a more
simplistic approach (and due to the need for quantita-
tive measurements), the central retinal thickness mea-
sured on OCT is often used as an objective measure
for i-CNV activity [44, 45].
Finally, several uveitides are characterized by the
presence of non-neovascular alterations occurring at
the level of the RPE, which induce changes in the ret-
ina and the choroid. OCT images can help in differ-
entiating such chorioretinal lesions from i-CNVs. In
multifocal choroiditis, for instance, acute inflamma-
tory foci are characterized by deeper penetration of
the OCT signal underneath the lesion. This sign is
usually absent in i-CNV [46, 47]. However, it must be
noted that distinguishing CNV lesions from inflam-
matory non-CNV lesions may be challenging on
OCT. Inflammatory chorioretinal lesions may present
with very similar features of outer retinal/RPE hyper-
reflectivity, intra-retinal edema, sub-RPE fluid, and
exudation. Such findings are common in conditions
such as MFC, PIC, TB SLC, and other conditions
with RPE/choriocapillaris involvement. In such situa-
tions, a combination of imaging tools such as FA and
ICGA, as well as OCTA, may be useful in determin-
ing the characteristics of the lesions [48].
Fig. 1 The detection of inflammatory choroidal neovascularization on fluorescein angiography in a patient with tubercular serpiginous-like choroiditis.
Fundus photograph of the right eye shows healed choroiditis lesions in the right eye (a) and the left eye (b). Fluorescein angiography of the right eye
shows early hyperfluorescent lesion in the foveal region (yellow arrowhead) (c). The late phase angiogram shows progressive hyperfluorescence of the
foveal lesion suggestive of choroidal neovascularization (yellow arrowhead) with staining of the healed choroiditis lesions (d)
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Optical coherence tomography angiography
Principle and algorithms of optical coherence
tomography angiography The development of OCTA
has revolutionized the study of pathogenesis, staging,
diagnosis, and management of CNV lesions in various
ocular conditions, especially AMD. OCTA helps in the
reconstruction of retinochoroidal microvascular network
by using endoluminal flow as contrast non-invasively
[49]. The development of OCTA has added a new di-
mension of functional vascular network imaging to the
existing capabilities of OCT allowing it to image
end-arterial system without the need of a dye injection
[50]. The OCTA devices commercially available consist of
various image processing algorithms. The most commonly
used algorithms include the following: (1) complex signal-
based OCTs, such optical microangiography (OMAG)
(Zeiss Angioplex ®, Carl Zeiss Meditec Inc., Dublin, CA); (2)
amplitude-based OCT signal, e.g., amplitude decorrelation
(Optovue AngioVue ®, Optovue, Inc., Fremont, CA); and (3)
speckle and phase variance. Each algorithm has its own ad-
vantages and limitations [51, 52]. With advancing technol-
ogy, there have been significant improvements in the OCTA
processing software. It is expected that new algorithms that
combine merits of various methods will become available to
achieve better image quality in the future. Presently, none of
the available algorithms are perfectly designed to identify
the retinochoroidal layers by automatic segmentation in all
the patients without any errors. In the context of uveitis,
automatic segmentation is even more challenging due to
the abnormalities involving the chorioretinal layers resulting
from scarring, choroiditis, intraretinal/subretinal fluid, and
other pigmentary changes [53, 54]. Therefore, caution must
Fig. 2 Multimodal imaging in a case of peripapillary inflammatory choroidal neovascularization (CNV) (sea fan type). a Combined fluorescein
angiography (FA) and indocyanine green angiography (ICGA) show multiple round hypofluorescent lesions in the mid-periphery with early
ill-defined hyperfluorescence on FA and area of hypocyanescence with ill-defined choroidal vessels on ICGA temporal to the optic disc. b In the
late phase FA, the mid-peripheral hypofluorescent lesions become less hypofluorescent/isofluorescent. There is a progressive increase in the
hyperfluorescence temporal to the optic disc on FA, suggestive of type 2 choroidal neovascularization. c Optical coherence tomography
angiography en face scan shows the presence of neovascular loops of vessels which have a sea fan configuration although the feeder
vessel is not apparent (yellow dashed circle). The scan has been obtained by manually segmenting the image to obtain a slab of 60 μm
thickness including the outer retina and choriocapillaris to allow better delineation of the pathology. d The corresponding structural en
face scan does not show any signal loss except in the areas of hard exudates. e The optical coherence tomography line scan passing
through the area of CNV shows the presence of a hyper-reflective lesion in the outer retina in the peripapillary region suggestive of type
2 CNV associated with retinal thickening and intraretinal cystoid spaces
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be exercised while interpreting the OCTA images in the
clinics. It is best to manually correct the segmentation and
assess the structural en face images to avoid false interpret-
ation due to artifacts such as shadowing and projection arti-
facts, among others.
To overcome the inherent limitations of OCTA, modern
techniques such as machine learning algorithms can en-
able more sophisticated image analyses and interpretation.
For instance, machine learning algorithms can allow identi-
fication of CNV by automated segmentation, improving the
accuracy of detection, permitting quantification, and delin-
eating the boundaries of the lesion [55]. In the future, such
techniques may be employed in the diagnosis of i-CNV.
Utility of optical coherence tomography angiography
in age-related macular degeneration Because of its
utility, OCTA is very useful in the assessment of neovas-
cular networks in neovascular AMD. Jia et al. first
reported that OCTA was able to detect and quantify
CNV in five eyes with AMD [56]. In a study by De Carlo
et al., the sensitivity of 50% (4 of 8) and specificity of
91% (20 of 22) was observed when OCTA was compared
to FA in their ability to detect CNV [57]. This relatively
low sensitivity was attributed to the small sample size
and presence of large retinal hemorrhages. OCTA is cap-
able of detecting type 1, type 2, and type 3 CNV lesions
in AMD [58, 59]. Various studies have compared the
sensitivity and specificity of OCTA with conventional
dye-based angiographies in detecting CNV. The sensitiv-
ities range from 50 to 87%, and specificities range from
91 to 100% [60–64].
OCTA is also useful in determining the characteristic
microvascular details of the CNV complex in AMD. This
allows detailed analyses such as quantification of the
area, evaluation of the branching pattern, and detection
of novel measures of CNV activity such as fractal ana-
lysis [65, 66]. Morphological pattern analysis of CNV on
OCTA has allowed identification of two major categor-
ies: (1) sea fan configuration with densely packed net-
works and capillary sprouts; and (2) medusa head
pattern with large diameter vessels sprouting from a
central vessel. OCTA has been shown to be useful in the
determination of biological markers of activity of the
CNV lesion, i.e., the presence of features such as perile-
sional halo, increased complexity of branching and capil-
lary sprouts, and alteration of choriocapillaris flow at the
margins are indicators of an active lesion [66, 67]. On
the other hand, lesions with large trunk vessels with
minimal branching indicate residual inactive networks in
AMD which may not require therapy.
In AMD, OCTA has enabled identification of CNV
lesions that are non-exudative and asymptomatic, i.e.,
treatment-naïve nascent lesions which can progress to
exudation and development of larger CNV lesions [68,
69]. Thus, OCTA can permit early identification of these
CNV lesions in AMD, potentially enabling the clinician
to initiate early therapy. Lastly, OCTA also provides
documentation of vascular remodeling and aids in the
understanding of the biological behavior of CNV net-
works in AMD [70]. This can provide insights into the
pathogenesis of the disease.
Fig. 3 Multimodal imaging of inflammatory choroidal neovascularization
(CNV) (medusa head appearance) in a case of multifocal choroiditis. a
The optical coherence tomography line scan passing through the fovea
shows a hyper-reflective lesion in the outer retina with the presence of
mild subretinal fluid suggestive of a type 2 CNV. b, c Optical coherence
tomography angiography (OCTA) en face 3 × 3 mm scan (along with
structural en face OCT scan) confirms the presence of a CNV lesion with
a medusa head appearance. Similar to Fig. 2, manual segmentation of
the scan has been performed to obtain a slab of 60 μm thickness
including the outer retina and choriocapillaris to allow better delineation
of the CNV. d The OCT line scan at 8-month follow-up after one
injection of intravitreal ranibizumab shows the persistence of outer
retinal hyper-reflectivity but resolution of subretinal fluid. e, f At this
visit, the OCTA en face scan (with corresponding structural en
face scan) shows a decrease in the size of the CNV lesion along
with a decrease in vessel caliber and branching
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In summary, OCTA has found innumerable applica-
tions in the assessment of CNV in AMD over the past
few years. The technology of OCTA in AMD is still
evolving and holds promise in improving the outcomes
in these patients.
Optical coherence tomography angiography in the
detection of inflammatory choroidal neovascularization
Compared to neovascular AMD, the applicability, useful-
ness, and limitations of OCTA in the evaluation of
i-CNV need to be explored in various areas. Similar to
neovascular AMD, OCTA can allow precise delineation
of i-CNV lesions in patients with uveitis. A number of
authors have shown the utility of OCTA as a non-inva-
sive modality in the detection of CNV.
In a study by Cheng et al., the ability to detect CNV and
differentiate it from the inflammatory lesions on OCTA
was assessed. In this series, 26 patients with a diagnosis of
multifocal choroiditis were evaluated using OCTA and
conventional FA [71]. Using FA, active type 2 CNV net-
works were identified in all the eyes. These findings were
also corroborated using OCTA. On OCTA, three eyes had
severe motion artifacts limiting the findings. The authors
concluded that OCTA has an advantage of differentiating
i-CNV lesions from inflammatory lesions as these do not
show any blood flow signals [71]. Similarly, in a recent
series by Zahid et al. [72], neovascular flow signals were
evaluated using OCTA in 14 patients with multifocal
choroiditis. Yee et al. demonstrated that OCTA allows
non-invasive diagnostic imaging of i-CNV and its
follow-up after therapy [73]. Thus, there are various case
reports in which OCTA has been used to detect neovascu-
lar flow lesions. OCTA allows non-invasive i-CNV detec-
tion in punctate inner choroidopathy [74], multifocal
choroiditis [46] and other white dot syndromes [75], ser-
piginous choroiditis [76], cat-scratch disease [77], and
TB-associated choroiditis [73]. In most of these published
studies, OCTA has been used to confirm the presence of
i-CNV networks in uveitis and demonstrate the neovascu-
lar regression following therapeutic intervention.
As mentioned earlier in the study by Cheng et al. [71],
OCTA particularly has an advantage over FA in distin-
guishing neovascular lesions from inflammatory lesions.
In a series of 13 patients (18 eyes) by Astroz et al. [48],
patients with multifocal choroiditis were evaluated using
various imaging tools to characterize inflammatory and
i-CNV lesions. The authors showed in their results that
on OCTA, i-CNV showed abnormal blood flow in al-
most all eyes and also in two lesions previously diag-
nosed as inflammatory lesions. Compared to other
imaging techniques, OCTA allowed a diagnosis of
i-CNV in additional 14% cases misdiagnosed as inflam-
matory lesions on other tools such as FA and OCT [48].
Certain published case reports have demonstrated dis-
tinct advantages of OCTA over conventional FA and
OCT in the detection of i-CNV, especially when the FA
and OCT are inconclusive. In a case report, Nozaki et al.
evaluated a patient of multiple evanescent white dot syn-
drome (MEWDS) and i-CNV using conventional FA,
OCT, and OCTA [75]. The authors observed that FA
showed significant leakage and pooling of dye due to
macular edema and serous retinal detachment. Similarly,
the OCT was inconclusive. It was only through OCTA
that the authors were able to observe a neovascular
complex and diagnose the presence of an i-CNV [75].
Similarly, Baumal et al. demonstrated in a young female
patient with multifocal choroiditis that OCTA can be
useful in confirming the presence of an i-CNV when the
conventional dye-based FA and SD-OCT was inconclu-
sive [78]. Levinson studied a larger cohort of 12 patients
with PIC and multifocal choroiditis of which 17 eyes had
suspected i-CNV lesions. In this study, the authors were
able to identify i-CNV in 15 eyes of 11 patients as a neo-
vascular network in choriocapillaris/outer retinal layer.
Among the seven eyes that underwent FA imaging,
i-CNV was detected in only four eyes using FA as an ab-
normal staining (but no clear-cut vessels were visible)
[74]. Another case report by Nakao et al. of a patient
with PIC showed the superiority of OCTA in detecting
i-CNV where FA showed only staining and possible leak-
age but was inconclusive [79].
Aggarwal et al. recently studied OCTA features of
TB-associated choroiditis and compared the findings to
conventional imaging including FA, ICGA, and OCT.
The study showed that OCTA, for the first time, was
able to identify type 1 neovascular networks in TB chor-
oiditis [80]. In this study, the authors showed that find-
ings were inconclusive on FA with only an ill-defined
hyperfluorescence in the late phase. ICGA also showed
only subtle ill-defined hyper-cyanescence that did not
confirm the presence of i-CNV. OCT showed only
low-lying pigment epithelial detachments but no intra-
or subretinal fluid. Thus, the manuscript concluded that
without OCTA, it is impossible to rule out neovascular
networks when FA, ICGA, and OCT are inconclusive
[80]. In addition, the presence of associated pathologies
such as chorioretinal scarring, choroiditis, and chorioret-
inal lesions may make it difficult to identify i-CNV
among patients with posterior uveitis [3]. Thus, the use
of OCTA provides objective evidence of the presence of
CNV lesions and greatly aids in the decision-making for
the use of anti-VEGF agents (Figs. 2 and 3).
Future directions of optical coherence tomography
angiography Studies with larger sample sizes and pro-
spective methodologies are needed to determine the
benefits of OCTA over conventional imaging such as
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FA, ICGA, and OCT in terms of sensitivity and specifi-
city. Unlike in AMD, quantitative analysis of i-CNV
lesions (such as area analysis, lesion size, vessel density
analysis, and fractal dimension analysis) have not been
performed thus far. Further studies are required that en-
able better correlation of FA, ICGA, and OCT with
OCTA especially in missed cases of i-CNV so that the
detection and treatment rates can be improved. While
evidence does show that OCTA may have several advan-
tages over conventional imaging, its disadvantages such
as motion artifacts, inaccurate segmentation, and projec-
tion artifacts need to be addressed. Studies that deter-
mine whether OCTA is able to detect i-CNV lesions
early and result in better visual outcomes need to be
planned in the future.
Near-infrared autofluorescence imaging
The technique of near-infrared autofluorescence (NIR AF)
using confocal scanning laser ophthalmoscope (SLO)
system has been employed in the study of various retinal
diseases. NIR AF originates from the melanin of the RPE
and has applicability in various conditions such as AMD
and CNV due to various causes [81–85]. Among patients
with neovascular AMD, NIR AF often shows signal block-
ade due to subretinal hemorrhage due to CNV. NIR AF
signal may be decreased in areas of exudation around the
CNV. NIR AF also allows adequate visualization of associ-
ated drusen in AMD CNV [85]. On the contrary, i-CNVs
may show a different pattern on NIR AF imaging, poten-
tially allowing differentiation between inflammatory le-
sions and neovascular membranes. NIR AF of active
lesions may show increased AF signal, whereas the i-CNV
may appear black/grayish with patchy AF signal [71].
Future studies are needed to further characterize the
appearance of inflammatory and i-CNV lesions on NIR
AF and explore whether this tool can be used to differenti-
ate between CNV related to AMD and other causes.
Management of inflammatory choroidal neovascularization
Anti-vascular endothelial growth factor therapy
Mechanism of action The development of anti-angio-
genic therapies based on the current understanding of
the molecular events in CNV has helped overcome a
barrier the management of CNV. Anti-VEGF drugs
pharmacologically target two crucial pathological changes
induced by VEGF: permeability and angiogenesis.
Anti-VEGF therapy for AMD Large multicenter ran-
domized controlled trials such as MARINA, ANCHOR,
and others have conclusively established the role of serial
anti-VEGF injections in AMD [28, 29, 86]. Anti-VEGF
therapy is, therefore, the treatment of choice for CNV sec-
ondary to AMD. Multiple studies have also demonstrated
the utility of anti-VEGF treatment in the management of
CNV secondary to other inflammatory etiologies. It is im-
perative to note however that unlike AMD, in i-CNV,
there are no randomized controlled trials (with double
masking and comparison to sham/alternate therapies)
testing the efficacy of anti-VEGF agents in the resolution
of the CNV or improving visual acuity. There are several
reasons for this, including the rarity of the CNV occur-
rence and heterogenous patient profile in terms of disease
manifestations, need for concomitant anti-inflammatory
therapy, and challenges in the diagnosis.
Efficacy of anti-VEGF in i-CNV Anti-VEGF therapies
have been used for the management of i-CNVs associated
with both infectious and non-infectious uveitic entities.
There are several case reports and case series document-
ing successful resolution of i-CNV following anti-VEGF
therapy, with or without concomitant anti-inflammatory
(either corticosteroid and/or immunosuppressive therapy).
Table 4 provides details of various relevant studies on the
efficacy of anti-VEGF therapy for i-CNV.
Role in infectious uveitis
Among patients with POHS, intravitreal injections of
anti-VEGF agents have been successfully used to treat
CNV. A retrospective case series of 28 patients presenting
either juxta- or subfoveal CNV related to POHS has dem-
onstrated that intravitreal bevacizumab leads to visual
acuity improvement in 71% eyes and a stabilization in 14%
of cases over an average follow-up of 22 weeks [87]. Simi-
larly, in ocular toxoplasmosis, Ben Yahia et al. [88] have
reported the effective use of bevacizumab in the successful
treatment of CNV due to ocular toxoplasmosis in two pa-
tients. Shah et al. [89] reported clinical improvement in
the treatment of CNV secondary to ocular toxoplasmosis
with a single administration of ranibizumab in a patient. A
few cases of CNV associated with ocular toxocariasis have
been managed with anti-VEGF agents. Lyall et al. [90] re-
ported a case of ocular toxocariasis with CNV treated with
intravitreal injection of ranibizumab. Yoon et al. [91] have
reported a similar case of toxocariasis with CNV treated
with intravitreal ranibizumab and bevacizumab injections
combined with oral albendazole. Julian et al. [92]
conducted a study involving 15 patients diagnosed with
CNV secondary to uveitis, including one patient with tu-
berculous uveitis. All the patients received intravitreal
bevacizumab injections for the treatment of CNV lesions.
At 17-month follow-up, nearly 80% of eyes showed signifi-
cant improvement in visual acuity and macular thickness
after a mean 4.25 injections. Kim et al. [93] reported a case
series of patients with active CNV as a result of tubercu-
lous chorioretinitis. The patients had a notable improve-
ment in their clinical course with the retention of their
baseline visual acuity.
Role in non-infectious uveitis
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Anti-VEGF therapies are also very efficacious in the
management of CNV associated with non-infectious uve-
itis. Wu et al. [94] reported successful outcomes of intra-
vitreal injections of bevacizumab for CNV associated with
VKH disease in two patients. Fine et al. [95] have reported
the outcome of bevacizumab and ranibizumab intravitreal
injections in 6 eyes affected by CNV secondary to multi-
focal choroiditis. The results at the end of follow-up
(mean follow-up 42 weeks, range 25–69 weeks) showed
an improvement of visual acuity values better than 20/30
and reduced activity of CNV lesion in 5 eyes. Another
retrospective study analyzed the efficacy of bevacizumab
administered for CNV not related to age-related macular
degeneration. This study included 12 eyes affected by
multifocal choroiditis [96]. Similarly, a recent case report
has described a favorable outcome after treatment of CNV
associated with serpiginous choroiditis with intravitreal
injection of ranibizumab [97]. While CNV is rarely associ-
ated with acute posterior multifocal placoid pigment
epitheliopathy (APMPPE), a single case report recently de-
scribes a 14-year-old girl who developed CNV associated
who was effectively treated with a single intravitreal rani-
bizumab injection with improvement in visual acuity from
20/40 to 20/20 through a follow-up of 12 months along
with the stabilization of the CNV [98].
Thus, anti-VEGF agents form the first-line therapy for
CNV lesions associated with ocular inflammation and
have been used to treat active CNV lesions in various in-
fectious as well as non-infectious uveitic entities.
Corticosteroid therapy
Mechanism of action Corticosteroids have been used
for decades and still represent the commonest choice in
the treatment of uveitis due to their strong and rapid
anti-inflammatory effects [99]. In addition to the inhib-
ition of pro-inflammatory factors, transcription and the
suppression of prostaglandin and interleukin synthesis,
corticosteroids interfere with the effects of VEGF [100,
101]. Reducing the VEGF stimulus to the growth of new
vessels and decreasing inflammation, the primary cause
for VEGF release, these drugs remain a valuable option
for the treatment of i-CNVs.
Role of oral corticosteroids Before anti-VEGF agents
became available, corticosteroid therapy was the only
medical option for the treatment of CNVs [102]. Patients
were usually treated with a course of 1 mg/kg/day of oral
corticosteroid for approximately 7 days followed by slow
tapering. With this approach, several authors reported
stabilization of visual acuity in more than 80% of the pa-
tients affected by subfoveal i-CNVs [2, 102]. High-dose
systemic corticosteroids can control ocular inflammation
as well as the stabilization of i-CNV lesions in patients
with posterior uveitis.
Local and intravitreal corticosteroids High-dose sys-
temic corticosteroids are limited by their adverse effect
profile. Martidis et al. conducted a study comparing
high-dose (1 mg/kg) oral prednisolone and a single
sub-Tenon injection of triamcinolone acetonide for sub-
foveal i-CNV due to POHS [102]. In this study, oral
prednisone resulted in a short-term improvement in vis-
ual acuity, which stabilized over longer follow-up. Sub-
Tenon’s triamcinolone group achieved similar final
stabilization without the initial improvement. Rechtman
et al. also evaluated the use of intravitreal triamcinolone
acetonide in ten patients with POHS [103]. Thirty percent
patients showed improvement, whereas 50% showed
stabilization in visual acuity. Intravitreal dexamethasone
implant (Ozurdex®) has not been employed in the man-
agement of i-CNV yet.
Combination therapies with corticosteroids
Local [104] or systemic [105, 106] steroid treatment
have been combined with photodynamic therapy (PDT),
allowing for a decrease in the number of PDT sessions
and, for the first time, to achieve an improvement in visual
acuity. Intravitreal corticosteroids (triamcinolone aceto-
nide) has been combined with bevacizumab for recurrent
i-CNV in VKH disease in a case report by Pai et al. [107]
The authors demonstrated complete resolution of i-CNV
and ocular inflammation after combined therapy and sys-
temic steroids until 1 year after follow-up.
When VEGF agents demonstrated favorable results in
patients affected by i-CNV (both in terms of visual out-
comes and their side-effect profile) [45], the use of corti-
costeroids alone or associated with PDT for the
treatment of this condition has gradually decreased. Des-
pite this, with inflammation being the primary trigger
for VEGF increase and consequent CNV development in
uveitis, corticosteroids are still considered a valuable op-
tion in the management of these conditions.
Limitations of the use of corticosteroids There are
currently no data available from randomized controlled
clinical trials comparing the efficacy of anti-VEGF agents
alone versus corticosteroids alone or as a combined
therapy. A proper guideline on the use of corticosteroids
in i-CNVs is conspicuously absent. In the face of uncer-
tainty, the wisest approach seems to be to control the in-
flammatory stimulus by the use of systemic steroids [1]
while simultaneously treating the neovascular compo-
nent with intravitreal injections of anti-VEGFs [19].
Immunosuppressive therapy
Pre-clinical evidence and mechanism of action Vari-
ous corticosteroid-sparing immunosuppressive agents
have been used as an off-label therapy in patients with
uveitis. As discussed in the preceding sections, most
cases with uveitis and i-CNVs are managed using
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systemic/local corticosteroids and anti-VEGF injections.
However, there are situations where corticosteroids may
be relatively contraindicated, such as patients with im-
paired steroid responsiveness or patients with a history
of severe systemic/ocular corticosteroid-related adverse
events. Immunosuppressive agents, by the virtue of their
anti-inflammatory action, can curb angiogenesis and
therefore limit the development of CNV.
In an experimental study of laser-induced CNV in
mice, the role of tumor necrosis factor (TNF)-α recep-
tors was evaluated [108]. CNV was induced in TNF-α
receptor 1a and 1b (−/−) mice and the expression of
TNF-α in the RPE, and the choroid was determined
using western blot analysis. In this experiment, it was
observed that TNF-α levels were elevated in the chorior-
etinal tissue in mice with CNV. The absence of TNF-α
receptors increased endothelial cell apoptosis and led to
a reduced inflammatory cellular response [108]. This ex-
periment provides a preclinical evidence of the use of
anti-TNF-α agents in the management of i-CNV. In a
murine model of laser-induced i-CNVs, the anti-TNF-α
agents (etanercept and infliximab) were shown to be
effective in decreasing the CNV size and leakage on
fluorescein angiography compared to the control group
[109]. These experiments support the role of immuno-
suppressive agents such as TNF-α in the management of
i-CNVs. At optimal doses, intravitreal injection of inflixi-
mab (an anti-TNF-α agent) in experimentally induced
CNV has been demonstrated to reduce the area of CNV
and decrease the levels of VEGF (by ELISA and im-
munofluorescence testing) without any cytotoxic effects
on the RPE [110].
Systemic immunosuppressive therapy Systemic im-
munosuppressive therapy can result in resolution of
i-CNV. A case report published in 1998 by Kilmartin et
al. demonstrates a case of a 3-year-old boy with sympa-
thetic ophthalmia who developed i-CNV resulting in the
worsening of visual acuity. Systemic cyclosporin resulted
in the stabilization of the lesion with resolution of asso-
ciated edema and hemorrhage [111]. In a series by Dees
et al., 14 patients (17 eyes) with i-CNV and posterior
uveitis were enrolled, of which 3 had extrafoveal CNV, 6
had juxtafoveal CNV, and 8 had subfoveal CNV. Of the
11 patients that received systemic immunosuppressive
therapy with agents such as cyclosporin, CNV resolved
in most eyes [112]. Neri et al. performed a prospective
open-label interventional study evaluating the efficacy of
systemic corticosteroids and mycophenolate mofetil for
controlling juxta/sub-foveal i-CNV, unresponsive to
traditional immunosuppressive therapy. Of the 12 eyes
(9 patients), all patients showed stable or reduced lesion
size at 12 months [113]. Ganesh et al. studied a large
series of 49 eyes (43 patients) with i-CNV. The authors
managed 17 eyes with systemic immunosuppressive
therapy with favorable results [114].
Immunosuppressive therapy may also be combined
with other forms of therapy such as PDT. In a retro-
spective study by Hogan et al., of the 6 patients, 2 with
subfoveal i-CNV were treated with systemic immuno-
suppression (oral mycophenolate mofetil). This approach
was effective in decreasing the fluorescein angiographic
leakage from i-CNVs. The authors showed that combin-
ation PDT and systemic immunosuppression was a
useful therapeutic option [115]. Systemic methotrexate
has also been used in combination with intravitreal rani-
bizumab in a patient with VKH disease complicated by
i-CNV [116].
Intravitreal immunosuppressive agents Intravitreal in-
jections of immunosuppressive agents may also be
employed in the management of i-CNV. Agents such as
intravitreal methotrexate may have a role in the manage-
ment of i-CNV as shown by Mateo-Montoya et al. In
this manuscript, the authors describe a case of a
25-year-old lady with multifocal choroiditis with i-CNV
who had received three prior injections of intravitreal
ranibizumab. The authors treated this patient with intra-
vitreal methotrexate (single injection) with improvement
in visual acuity and no recurrence of CNV lesion at
20 months follow-up [117]. While there are very few
such published reports, we have had success in treating
i-CNV with intravitreal methotrexate, in patients who
either cannot tolerate or afford other forms of therapy.
Advantages and limitations of the use of immunosup-
pressive agents Knowledge of the use of immunosup-
pressive agents for i-CNVs is increasing with passing
time. However, there are no clear guidelines on the use
of these agents, nor on the choice of agents for man-
aging i-CNVs. The exact mechanisms by which im-
munosuppressive therapies act on the CNV is not yet
clear. Therefore, further studies that evaluate the efficacy
of immunosuppressive therapies (systemic and/or local)
that highlight the choice of the agent, timing and num-
ber of injections, and outcome measures are necessary.
Since there are no guidelines on the use of anti-VEGF,
corticosteroid or immunosuppressive therapies for i-CNV,
a randomized clinical trial is necessary. In the context of
uveitic macular edema, where a similar dilemma exists,
the National Eye Institute (NEI) is currently recruiting pa-
tients in a multicenter clinical trial, Macular Edema Rani-
bizumab versus Intravitreal Anti-inflammatory Therapy
Trial (MERIT), to evaluate the relative efficacy and safety
of intravitreal methotrexate, intravitreal ranibizumab, and
the intravitreal dexamethasone implant [118]. A similar
approach is needed for the management of i-CNVs.
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Other therapeutic strategies
Other various therapeutic strategies have been used in
the literature in the management of i-CNVs. These have
been summarized in the following sections.
Photodynamic therapy As mentioned in the preceding
sections, PDT has been variably used in the management
of CNV associated with uveitis, often combining it with
anti-VEGF therapy or corticosteroids. The consensus of
the use of PDT alone is that it can stabilize but can
rarely improve the visual acuity. PDT with verteporfin
has been used in the monotherapy of CNV associated
with serpiginous choroiditis, POHS, and PIC [119–121].
In a prospective pilot study of 19 patients with i-CNV,
standard PDT with verteporfin was performed for
patients with diagnoses of PIC, POHS, and multifocal
choroiditis. The authors suggested that PDT may per-
form better in CNV due to ocular inflammation com-
pared to AMD over a period of 1 year [122]. However,
the exact reasons for this is not clear.
Long-term results of PDT have been extensively studied
in CNV lesions occurring in association with toxoplasma
retinochoroiditis. In a study of 8 patients, classic or pre-
dominantly classic CNV was treated using PDT. Persistent
CNV regression was achieved in all the patients at 2 years
[123]. Neri et al. evaluated the long-term (4-year) outcome
of PDT in CNV lesions associated with toxoplasmosis in 9
patients. The authors observed stable/improved visual
acuity and stabilized CNV diameters after PDT at 4 years’
follow-up [124]. In other case reports, PDT has been com-
bined with either bevacizumab or with intravitreal triam-
cinolone acetonide in the treatment of CNV associated
with toxoplasmosis [125, 126].
PDT has also been employed in the management of
CNV lesions associated with other pathologies such as
VKH disease [127, 128]. Nowilaty et al. performed PDT
in six eyes of 6 patients with VKH disease who devel-
oped CNV. Three eyes showed the development of sub-
macular fibrosis. All the eyes showed stabilization of
visual acuity and CNV lesions [127]. However, in an-
other case report, retinal pigment epithelial alterations
raised concerns following PDT for CNV associated with
VKH disease [128].
Among patients with multifocal choroiditis, PDT has
been performed either as a monotherapy [129] or in com-
bination with immunosuppression [115] or anti-VEGF
agents [130]. In all these series, PDT was associated with
stabilization of CNV and visual acuity. In summary, PDT
is rarely used as monotherapy for managing i-CNV in the
present times.
Surgical excision Surgical excision of CNV lesions was
a historical treatment modality that has gone out of
favor in the modern era. This treatment option was
selected by ophthalmologists when the sole alternative
therapy was laser photocoagulation, which often resulted
in visual loss. In a series of 43 eyes of 40 patients with
CNV not to related AMD by Benson et al., surgical exci-
sion of the subfoveal CNV lesions was performed. In this
series, 79% patients showed either improved or un-
changed visual acuity following surgery. Recurrence of
CNV was noted in 23% eyes for whom repeat surgery
was performed [131]. CNV lesions in toxoplasma retino-
choroiditis [132] and candida endophthalmitis [133, 134]
have been also treated using submacular surgery.
In the era of anti-VEGF therapy, submacular surgery
has not found popularity. Thus, this treatment option is
no longer preferred and very rarely, if ever, employed in
present-day clinical practice.
Conclusions
The detection of CNV is challenging in patients with
uveitis due to the difficulties of visualizing the lesion
amidst choroiditis lesions, scarring, and pigmentation.
Based on various case reports and series evaluating pa-
tients of posterior uveitis with suspected i-CNV, it can
be concluded that OCTA in conjunction with FA, ICGA,
and OCT can help in improved detection of CNV le-
sions, especially in cases where conventional imaging is
inconclusive. OCTA can also be used to non-invasively
follow-up such lesions. Importantly, there should be a
high index of suspicion for identifying neovascular flow
lesions that may be considered to be inflammatory le-
sions on examination and conventional imaging. Inter-
pretation of OCTA requires careful review of the images
to exclude any image artifacts and incorrect segmenta-
tion errors. Since the current OCTA are first generation
devices, further improvement in technology may ad-
vance our imaging capabilities. As shown in various re-
ports, OCTA is a very useful modality in the diagnosis
and follow-up of i-CNV lesions, and further studies may
help evaluate its role in determining the endpoint for
treatment.
FA and ICGA, the two gold standard dye-based angio-
graphic techniques, provide significant information regarding
the retinochoroidal pathology in uveitis, including the level
and severity of inflammation, presence of focal lesions, and
vascular changes including neovascularization. OCTA ap-
pears to provide certain advantages over these existing tools
in the detection of neovascular flow lesions in uveitis but cer-
tainly does not replace the information provided by the other
imaging tools in the present times. Thus, while OCTA is a
promising and exciting tool, significant advancements in the
technology are needed to establish its role in the practice of
uveitis and ocular inflammation.
Many treatment modalities are available in the man-
agement of i-CNV associated with uveitis. The general
principle of treatment is to limit the inflammatory
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response with corticosteroids and/or immunosuppressive
agents. If the inflammation is unilateral, local therapies
such as intravitreal dexamethasone implant, methotrexate,
or triamcinolone acetonide can be considered, which can
also help to reduce the size of the CNV lesion. Anti-VEGF
agents are highly efficacious and are usually employed as
the first-line agents for treating CNV associated with uve-
itis, keeping in mind that the inflammation needs to be
controlled for the best outcome and reduction of recur-
rences. PDT is uncommonly used in the anti-VEGF era
due to its limitations in improving visual acuity and
potential adverse effects. In the future, novel anti-inflam-
matory agents and immunosuppressive agents, including
intravitreal injections, may become available for the man-
agement of i-CNV.
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